Michael Houghton net worth and biography

Michael Houghton Biography and Net Worth

Director of Assembly Biosciences

Dr. Houghton has been a director since 2021 and currently serves as Director of the Li Ka Shing Applied Virology Institute at the University of Alberta in Edmonton. Since joining the University in 2010 as Canada Excellence Chair in Virology, he has served as a Li Ka Shing Professor in the Department of Medical Microbiology and Immunology. Dr. Houghton has also served as Chief Scientific Officer at Applied Pharmaceutical Innovation in Canada since 2023. Previously, he was Chief Scientific Officer at Epiphany Biosciences and Vice President of hepatitis C and virology research at Novartis Vaccines and Diagnostics. Earlier in his career, Dr. Houghton spent 24 years in hepatitis C and virology research at Chiron Corporation. He began his career as senior research investigator working on human interferon genetics at Searle Research Laboratories in Buckinghamshire, England. Dr. Houghton earned a BSc in biological sciences from the University of East Anglia, and a PhD in biochemistry from King’s College, University of London. Over the course of his career, he has been the recipient of 17 prestigious awards, including the Lasker Award and, most recently, the Nobel Prize in Physiology or Medicine. Additionally, Dr. Houghton was knighted in the 2021 Queen’s Birthday Honours for services to medicine.

What is Michael Houghton's net worth?: The estimated net worth of Michael Houghton is at least $85.30 thousand as of December 30th, 2024. Houghton owns 3,202 shares of Assembly Biosciences stock worth more than $85,301 as of March 30th. This net worth evaluation does not reflect any other assets that Houghton may own. Learn More about Michael Houghton's net worth.
How do I contact Michael Houghton?: The corporate mailing address for Houghton and other Assembly Biosciences executives is 331 OYSTER POINT BOULEVARD FOURTH FLOOR, SOUTH SAN FRANCISCO CA, 94080. Assembly Biosciences can also be reached via phone at (833) 509-4583 and via email at [email protected]. Learn More on Michael Houghton's contact information.
Has Michael Houghton been buying or selling shares of Assembly Biosciences?: Michael Houghton has not been actively trading shares of Assembly Biosciences over the course of the past ninety days. Most recently, on Monday, December 30th, Michael Houghton bought 3,202 shares of Assembly Biosciences stock. The stock was acquired at an average cost of $15.61 per share, with a total value of $49,983.22. Following the completion of the transaction, the director now directly owns 3,202 shares of the company's stock, valued at $49,983.22. Learn More on Michael Houghton's trading history.
Who are Assembly Biosciences' active insiders?: Assembly Biosciences' insider roster includes Jeanette Bjorkquist (Insider), William Delaney (Insider), Michael Houghton (Director), John McHutchison (CEO), Jason Okazaki (CEO), and Timothy Springer (Director). Learn More on Assembly Biosciences' active insiders.
Are insiders buying or selling shares of Assembly Biosciences?: During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 1,292 shares worth more than $12,726.20. The most recent insider tranaction occured on March, 31st when insider Jeanette M Bjorkquist sold 180 shares worth more than $1,773.00. Insiders at Assembly Biosciences own 5.1% of the company. Learn More about insider trades at Assembly Biosciences.
Information on this page was last updated on 3/31/2025.

Michael Houghton Insider Trading History at Assembly Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/30/2024	Buy	3,202	$15.61	$49,983.22	3,202

Michael Houghton Buying and Selling Activity at Assembly Biosciences

Assembly Biosciences Company Overview

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Today's Range

Now: $26.64

$26.32

$28.12

50 Day Range

MA: $27.93

$25.39

$29.95

2 Week Range

Now: $26.64

$7.75

$39.71

Volume

72,596 shs

Average Volume

97,302 shs

Market Capitalization

$422.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11